Novartis new two-year data with Certican® shows positive outcomes at 24 months in largest liver transplant trial to date
» Report
Einige Inhalte dieser Seite sind nur für Abonnenten sichtbar.
Anmelden oder
Jetzt abonnieren!
Richemont 2023/24: Umsatz 20'616 Mio, EBIT 4794 Mio, Reinergebnis 2355 Mio EUR; Dividende 2,75 CHF! ABB erweitert Elektrifizierungsportfolio durch Übernahme der Wiring-Accessories-Sparte von Siemens in China! Logitech reicht Jahresbericht auf Formular 10-K ein! Arbonia übernimmt tschechischen Marktführer im Objektbereich Lignis! R&S Group hebt Ausblick für 2024 und Mittelfristprognose an!
SGS acquires the Ware Care Group, NL
» Report
Alpiq führt Restrukturierungsprogramm weiter
» Report
Novartis data show ACZ885 delivered rapid and strong symptom relief while reducing frequency of attacks in two periodic fever syndromes
» Report
Zehnder: Verlangsamtes Umsatzwachstum und weiterhin hohe Investitionen
» Report
Pargesa: Consolidated results 3Q 2012 (unaudited)
» Report
Ein schönes Wochenende
Joint Press Release Board of Governors of the Federal Reserve System, Federal Deposit Insurance Corporation, Office of the Comptroller of the Currency: Agencies Provide Guidance on Regulatory Capital Rulemakings
» Report
Neuemissionen ZKB Warrants
» Report
Italian authorities lift precautionary hold on Novartis seasonal influenza vaccines
» Report
IN ZEICHNUNG: JB Barrier Reverse Convertibles
» Report
CREDIT SUISSE NEW ISSUE: 8 Warrants on UBS, 4 Call(s), 4 Put(s)
» Report
UBS NEW ISSUE Stable Income & Full Upside: 5% p.a. CHF Kick-In GOAL with Participation on Nestlé, Roche, Zurich Insurance
» Report
CREDIT SUISSE NEW ISSUE: 8 Warrants on Zurich Insurance Group, 4 Call(s), 4 Put(s)
» Report
UBS issued a new 8.50% p.a. USD Early Redemption Kick-In GOAL on Worst of Nasdaq 100 / Russell 2000 / S&P 500 / S&P/TSE 60 (Valor 11406457) directly in the secondary market.
UBS issued a new 7.00% p.a. CHF Early Redemption Kick-In GOAL on Worst of Euro STOXX 50 / Nikkei 225 / SMI / S&P 500 (Valor 19946174) directly in the secondary market.
IN SUBSCRIPTION: JB Callable Multi Barrier Reverse Convertibles auf Versorger- und Goldminen-Aktien
» Report
Credit Suisse: Products in Subscription
» Report
Novartis announces update to company's Board of Directors to take effect in February 2013
» Report
Richemont: Changes to senior management
» Report
Partners Group: Accelerated book built offering priced at CHF 183 per share allowing Partners Group founders to invest a minimum of CHF 300 million alongside clients and to materially increase the free float
» Report
Richemont announces its unaudited consolidated results for the six month period ended 30 September 2012
» Report
“Novartis is focused on innovation to address unmet medical needs for patients,” said Joe Jimenez, CEO, at R&Dday
» Report
Mario Draghi, President of the ECB: Introductory statement to the press conference
» Report
Neuemission ZKB Strukturierte Produkte
» Report
EZB PRESSEMITTEILUNG: Geldpolitische Beschlüsse
» Report
Bank of England maintains Bank Rate at 0.5% and the size of the Asset Purchase Programme at £375 billion
» Report
Zurich - News Release: Isabelle Welton appointed Group Chief Marketing Officer
» Report
BLW - Die Bevölkerung steht zur Schweizer Landwirtschaft
» Report
KOF/KOF Konjunkturumfragen vom Oktober: Schlechtere Geschäftslage bei Schweizer Unternehmen
» Report
Nestlé opens first research and development centre in India
» Report
Schweiz: UBS senkt BIP-Prognose 2013 auf 0,9% von 1,4%
» Report
Swisscom: Neue Mobilfunkangebote sehr erfolgreich - Schweizer Geschäft insgesamt leicht rückläufig – höhere Investitionen – Fastweb auf Kurs
» Report
Novartis future growth prospects secured by industry-leading pipeline, with more than 139 projects with 73 new compounds
» Report
Swiss Re reports very strong net income of USD 2.2 billion for third quarter of 2012, driven by Property & Casualty Reinsurance and Admin Re® US sale
» Report
Nobel Biocare reports improved profits in a declining market
» Report
Kuoni: higher turnover and improved operating earnings in the first nine months of 2012
» Report
Groupe BCV: très bons résultats avec un bénéfice brut en hausse
» Report
Novartis drug Signifor® recommended by FDA advisory committee for approval to treat patients with Cushing's disease
» Report
Zurich News Release: BCI Supply Chain Resilience Survey 2012
» Report